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Background: The benefit of surgical resection of liver metastases from gastric cancer has not been well established.
The aim of this study was to evaluate the rationale for hepatic resection in patients with hepatic metastases from
gastric cancer.
Methods: Among 10 259 patients diagnosed with gastric adenocarcinoma in the Yonsei University Health System
from 1995 to 2005, we reviewed the records of 58 patients with liver-only metastases from gastric cancer who
underwent gastric resection regardless of hepatic surgery.
Results: The overall 1-year, 3-year, and 5-year survival rates of 41 patients who underwent hepatic resection with
curative intent were 75.3%, 31.7%, and 20.8%, respectively, and three patients survived >7 years. Of the 41 patients,
22 had complete resection and 19 had palliative resection. Between the curative and palliative resections, survival
rates after curative intent were not different. The number of liver metastasis (solitary or multiple) was a marginally
significant prognostic factor for survival.
Conclusions: Surgery for liver metastases arising from gastric adenocarcinoma is reasonable if complete resection
seems feasible after careful preoperative staging, even if complete resection is not actually achieved. Hepatic resection
should be considered as an option for gastric cancer patients with hepatic metastases.
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introduction
The optimal treatment of gastric cancer with liver metastases
without peritoneal dissemination or other distant metastases
remains a matter for debate. In such patients, the continuing
question is whether it is beneficial to resect both the primary
gastric cancer and hepatic metastases as the only potential
opportunity for a cure.
Around 5%–14% of patients who undergo surgery for gastric
cancer develop liver metastases synchronously or
metachronously [1–5]. Long-term survival is usually hard to
achieve following metastatic liver involvement from gastric
cancer with a median survival of 6 months, even with
palliative chemotherapy [4, 6, 7]. Many studies have reported
on the benefit of hepatic resection for metastatic tumors
from colorectal cancer [8–12]. In contrast, the significance of
hepatic resection for gastric metastases has been controversial
[2–4, 9, 13–16]. A number of studies have found that the effect
on survival of hepatic resection for hepatic metastases from
gastric cancer is doubtful [17–20], while others indicate that
only hepatic resection leads to long-term survival [2, 5, 12–16,
21–26]. These reports describe that 5%–30% of enrolled
patients survive for >5 years after hepatic surgery.
In Western countries, hepatic resection in gastric cancer
patients is seldom indicated because of the presence of multiple
tumors or associated peritoneal dissemination [4, 13, 27].
Peritoneal metastases are recognized in 40% of gastric cancer
patients with liver metastases. For these reasons, most surgeons
hesitate to perform hepatic resection, even if only a solitary
hepatic metastasis may be involved. However, because one of
the most important factors in the prognosis of gastric cancer
is liver metastasis, complete surgical resection of the primary
gastric tumor and liver metastases appears to be the only
chance to cure this disease. One possible explanation for the
persistent controversy may be the lack of sufficient data in
a relatively large number of patients undergoing hepatic
resection for gastric cancer metastases. To our best knowledge,
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only one report has included >40 patients [13]. In addition,
all previous reports have been retrospective analyses of
heterogeneous patients. Thus far, little is known about
prognostic factors in patients with liver surgery for gastric
cancer metastases.
We evaluated the possible beneficial effect of hepatic
resection on survival in gastric cancer with hepatic metastases
and identified patients who might benefit from combined
curative surgery.
patients and methods
patients
From January 1995 to December 2005, 10 259 patients were diagnosed with
gastric adenocarcinoma in the Yonsei University Health System, South
Korea. Of these 10 259 patients, 1013 patients (9.9%) had synchronous
or metachronous liver metastases. Among these 1013 patients,
84 underwent gastric resection. Fifty-eight patients with liver-only
metastases among these 84 patients who underwent gastric resections
regardless of hepatic operation were included in this study (Figure 1). This
study included patients who underwent hepatic surgical resection including
radiofrequency ablation (RFA) and those who did not undergo hepatic
resection for metastatic hepatic tumors but did surgical treatment of the
gastric cancer. Patients who received prior chemotherapy before surgery
were excluded. The median follow-up period was 15.5 months (range
0.5–106.8 months).
methods
evaluation of clinical and tumor characteristics. The following demographic
and clinicopathological information was retrospectively obtained from
patient records: age, gender, interval between gastrectomy and hepatic
surgery, types of surgical procedures, characteristics of primary gastric
cancer and liver metastases, postoperative chemotherapy, and relapse
pattern. Characteristics of the primary gastric cancer included depth of
invasion, extent of lymph node metastasis, pathologic type, tumor
differentiation, tumor location, tumor size, and surgical margin.
Characteristics of hepatic metastases included the number, size, lobar
distribution, time to liver metastasis, and surgical margin of the resected
tumors. Pathological staging was determined according to American Joint
Committee on Cancer criteria (6th edition, 2002).
definition of curative gastric surgery (D2 surgery). Curative gastric resection
included the absence of residual tumor, both macroscopically and
microscopically, by D2 lymphadenectomy with omentectomy and
splenectomy. For D2 lymphadenectomy, all perigastric lymph nodes, those
along the left gastric, common hepatic, celiac arteries, and retropancreatic
lymph nodes were removed. Splenectomy was carried out only in cases of
documented lymph node enlargement at the splenic hilum.
indications of hepatic surgery or RFA. Curative hepatic resection was defined
as macroscopically and microscopically undetectable tumors. Indications
for resection of hepatic metastases included (i) no signs of peritoneal
dissemination or any other distant metastases on preoperative imaging,
(ii) feasibility of complete tumor resection including primary gastric cancer
and hepatic metastases, and (iii) acceptable hepatic function on the basis
of serum liver function test panel. Patients with hepatic metastases from
gastric cancer who seemed to be inappropriate candidates for curative
hepatic resection due to the number, size, and location of hepatic tumors
were evaluated for RFA. Indications of RFA included (i) no signs of
peritoneal dissemination or any other extrahepatic distant metastasis on
preoperative imaging, (ii) probably impossible hepatic resection on
the basis of the location, size, or number of hepatic metastases,
(iii) unresectability as determined by the surgeon based upon intraoperative
Figure 1. Grouping of enrolled patients.
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findings of number, size, and location of tumors as well as comorbid
conditions, and (iv) presence of hepatic tumors £5 cm.
patient groups. We classified the patients into three groups. Group A
included patients who underwent combined curative resection of gastric
cancers and hepatic metastases (n = 22). Group B patients underwent
both gastric and hepatic surgery with curative intent, but at least one
surgery was ultimately palliative due to microscopically or macroscopically
residual disease (n = 19). Group B included nine patients treated with RFA,
eight resection margin-positive patients, and two patients with residual
cancer. RFA was carried out with curative intent but was ultimately
defined as a palliative intervention. Among the eight resection
margin-positive patients, seven had residual microscopic cancer cells at
the hepatic resection margin and one at the stomach. The two patients
with residual cancer were considered for curative resection on initial
preoperative examination, but surgery revealed too many liver metastases,
making curative resection impossible. Group C included patients who
underwent gastric resection in the presence of untreated liver-only
metastases (n = 17) (Figure 1).
follow-up. Overall survival after hepatic metastases was defined as the
time from diagnosis of liver metastases in both synchronous and
metachronous types to death from any cause or last follow-up. Relapse-free
survival in the curatively resected group (Group A, n = 22) was defined
as the time from diagnosis of liver metastases to the first documentation
of recurrence or last follow-up.
statistics. Data related to patient characteristics were compared among
the three groups using an analysis of variance for continuous variables
and the chi-square test or Fisher’s exact test for categorical end points. Data
on patients who were alive or lost to follow-up were censored. Data on
patients who were alive and free of recurrent disease were censored at
the time of the last follow-up visit.
Survival curves were estimated by the Kaplan–Meier method, and the
differences in survival curves among groups were compared with the
log-rank test. In order to adjust for confounding variables, we used Cox
proportional hazards models to estimate the simultaneous effects of
prognostic factors on survival. Hepatic resection margins were not included
in this analysis because some of the margins were not recorded on
a numeric scale (millimeter), but rather as presence of tumor cells
(negative or positive). All statistical tests were two sided, and P < 0.05 was
considered statistically significant. SAS software (version 9.1, SAS Inc., NC)
was used for statistical analysis.
results
patient characteristics
The baseline characteristics of eligible patients are presented
in Table 1. There were 49 men and 9 women with a median age
of 61 (range 36–74) years. There were no major imbalances
between groups in terms of characteristics of primary gastric
cancer except with regard to the number and distribution of
hepatic metastases. The number of patients with a solitary
metastasis was 18 (81.8%) in group A, 10 (52.6%) in group B,
and 1 (5.9%) in group C, respectively (P < 0.0001). In group A,
the location of the tumors was unilobar in 21 patients
(95.5%) and bilobar in 1 (4.5%). In groups B and C, the
proportion of patients with bilobar distribution of hepatic
metastases was 21.1% and 64.7%, respectively. Patients with
unresected hepatic metastases (group C) showed more
multiple hepatic metastases and bilobar distribution. Hepatic
metastases were detected synchronously in 18 patients and
metachronously in 4 patients in group A.
In patients who underwent metachronous liver resection,
the median interval between gastric resection and the
diagnosis of hepatic metastases was 19.1 months in total
(range 8.0–38.2 months), 12.8 months in group A
(range 8.9–19.1 months), and 25.9 months (range 8.0–38.2
months) in group B.
Table 1. Patient characteristics
Characteristics Number of patients (%) P value
Group A
(n = 22)
Group B
(n = 19)
Group C
(n = 17)
Sex
Male 18 (81.8) 16 (84.2) 15 (88.2) 0.9047
Female 4 (18.2) 3 (15.8) 2 (11.8)
Age (median years) 59 (40–74) 60 (36–70) 61 (52–74) 0.3693
Primary gastric cancer
Serosal invasion
Absent 3 (13.6) 3 (15.8) 2 (11.8) 1.0000
Present 19 (86.4) 14 (73.7) 15 (88.2)
NA – 2 (10.5) –
Lymph node metastasis
Absent 3 (13.6) 3 (15.8) 2 (11.8) 1.0000
Present 19 (86.4) 14 (73.7) 15 (88.2)
NA – 2 (10.5) –
Histologic grade
Poorly differentiated 9 (40.9) 5 (26.4) 9 (52.9) 0.3391
Moderately
differentiated
12 (54.5) 10 (52.6) 8 (47.1)
Well differentiated 1 (4.6) 2 (10.5) 0 (0)
NA – 2 (10.5) –
Tumor location
Upper body 5 (22.7) 4 (21.1) 4 (23.5) 0.8135
Mid-body 2 (9.1) 4 (21.1) 2 (11.8)
Lower body 15 (68.2) 9 (47.3) 11 (64.7)
NA – 2 (10.5) –
Tumor size
(mean cm 6 SD)
5.7 6 2.4 6.6 6 3.1 6.1 6 2.3 0.5754
Hepatic metastasis
Number
Solitary 18 (81.8) 10 (52.6) 1 (5.9) <0.0001
Multiple 4 (18.2) 9 (47.4) 16 (94.1)
Metastatic type
Synchronous 18 (81.8) 12 (63.2) 12 (70.6) 0.4049
Metachronous 4 (18.2) 7 (36.8) 5 (29.4)
Distribution
Unilobar 21 (95.5) 15 (78.9) 6 (35.3) <0.0001
Bilobar 1 (4.5) 4 (21.1) 11 (64.7)
Tumor size
(mean cm 6 SD)
2.4 6 1.7 2.1 6 1.4 NA 0.6387
Group A: combined curative resection of gastric cancers and hepatic
metastases. Group B: gastric and hepatic resection with curative intent,
where at least surgery was ultimately only palliative. Group B includes
radiofrequency ablation for hepatic metastases. Group C: palliative gastric
resection in the presence of untreated liver-only metastases.
NA, not applicable; SD, standard deviation.
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treatments
Fifteen and eleven partial gastrectomies and seven and eight
total gastrectomies were carried out with curative intent in
groups A and B, respectively. In group C, 11 patients
underwent partial gastrectomies and 6 patients total
gastrectomies. In terms of the type and extent of hepatic
resection, wedge resection was done in 59.1% of cases in
group A and 42.1% of cases in group B. RFA was carried out in
47.4% of cases and lobectomy was not carried out in group B.
Table 2 details the type of hepatic surgery in each group.
Overall postoperative hospital mortality was 1.72% (1 of 58).
Excluding patients who underwent RFA, complete resectability
of surgical procedures was 68.8% (22 of 32).
A total of 51 patients (87.9%) received postoperative
chemotherapy. Among those who underwent curatively
intended gastric and hepatic surgery (n = 41), 37 (90.2%)
received postoperative chemotherapy. Anthracycline- and
cisplatin-based chemotherapies were the most common
chemotherapy regimens.
recurrence
Cancer recurred in 14 (63.6%) of the 22 group A patients
who underwent curative resection. The most common site of
initial recurrence after hepatic resection was the liver (n = 11;
78.6%). Relapse pattern is summarized in Table 3. Median
relapse-free duration of the curatively resected group was
13.3 months (Figure 2A). We evaluated the potential effect
of prognostic factors known to influence recurrence in the
Table 2. Type of hepatic surgery
Type of hepatic surgery Number of patients (%)
Group A (n = 22) Group B (n = 19)
Wedge resection 13 (59.1) 8 (42.1)
Segmentectomy 6 (27.3) 2 (10.5)
Lobectomy 3 (13.6) 0 (0)
Radiofrequency ablation 0 (0) 9 (47.4)
Group A: combined curative resection of gastric cancers and hepatic
metastases. Group B: gastric and hepatic resection with curative intent,
where at least surgery was ultimately only palliative. Group B includes
radiofrequency ablation for hepatic metastases.
Table 3. Relapse patterns in 22 curatively resected patients (group A)
Number (%)
Relapse 14 (63.6)
Local relapse only 0
Systemic relapse only
(except liver)
3
Intrahepatic relapse only 6
Intrahepatic and systemic
relapse
5
Relapse free 8 (36.4)
Group A: combined curative resection of gastric cancers and hepatic
metastasis.
Figure 2. (A) Relapse-free survival of patients receiving curative resection
(group A) and overall survival of all patients. (B) Overall survival of each
group (A, B, and C). (C) Overall survival comparing patients who
underwent hepatic resection with curative intent (groups A and B) with
patients who underwent palliative gastrectomy without hepatic resection
(group C).
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curatively resected group and found no significant relationships
(data not shown).
The most common site of recurrence in the nine patients that
received RFA was also the liver (n = 7; 77.8%). Site of
recurrence could not be evaluated in six of eight patients who
had a positive resection margin due to follow-up loss. Of the
remaining two patients, one had liver recurrence and the other
had systemic recurrence.
survival
We examined survival in two different ways. First, we
compared the overall survival of groups A, B, and C. Second,
we compared the survival of patients who received hepatic
resection with curative intent regardless of actual curative or
palliative outcome to those who were unresected.
The median overall survival of patients in groups A, B, and C
was 17 months (range 0.6–106.8 months), 21.7 months (range
3.7–53.3 months), and 8.1 months (range 1.3–19.6 months),
respectively. Adjustment for sex, age, number of liver
metastases (solitary versus multiple), and hepatic metastatic
type (synchronous versus metachronous) resulted in hazard
ratios for death of 0.512 (P = 0.1963) in group A and 0.309
(P = 0.01) in group B compared with group C (Table 4). The
1-year, 3-year, and 5-year survival rates were 77%, 30.4%, and
22.8% in group A; 73.7%, 33.8%, and 0% in group B; and
29.4%, 0%, and 0% in group C, respectively. There was no
statistically significant difference in survival rate at 1 and
3 years between groups A and B (Figure 2B), but there were
long-term survivors in group A on the basis of 5-year survival
rates. Three out of 22 patients in group A survived >7 years.
Next, we classified the patients into two groups (groups A
and B versus group C) on the basis of the curative or palliative
intent of the surgical resection, namely whether liver directed
treatment or not. The 1-year, 3-year, and 5-year survival rates
in the hepatic resection group with curative intent (groups A
and B including RFA) were 75.3%, 31.7%, and 20.8%,
respectively, while in the hepatic unresected group (group C)
the rates were 29.4%, 0%, and 0%, respectively (P < 0.0001)
(Figure 2C). The survival benefit of groups A and B (that
underwent hepatic surgery with curative intent) was a 20.8%
improvement in the 5-year survival rate compared with group
C, corresponding to a 64.0% reduction in the risk of death after
adjusting for sex, age, number of liver metastases (solitary
versus multiple), and hepatic metastatic type (synchronous
versus metachronous) (Table 5).
RFA also showed comparable outcomes to curative
resection (Figure 3). There was one cancer-unrelated
mortality in group A in a patient who died of septic shock
not related to surgery or chemotherapy.
Table 4. Multivariate analysis of hazard ratio for death in each group
(n = 58)
Variable P value Hazard ratio
Sex 0.6837 1.199
Age 0.1846 1.027
Group Aa 0.1963 0.512
Group Bb 0.0103 0.309
Hepatic tumor number
(solitary versus multiple)
0.0814 2.171
Hepatic metastatic type
(synchronous versus
metachronous)
0.4437 1.320
Group A: combined curative resection of gastric cancers and hepatic
metastases. Group B: gastric and hepatic resection with curative intent,
where at least surgery was ultimately only palliative. Group B includes
radiofrequency ablation for hepatic metastases. Group C: palliative gastric
resection in the presence of untreated liver-only metastases.
aGroup A versus group C.
bGroup B versus group C.
Table 5. Multivariate analysis of hazard ratio for death in patients who
underwent surgical procedures with curative intent (groups A and B)
compared with palliative intent (group C) (n = 58)
Variable P value Hazard ratio
Sex 0.6024 1.261
Age 0.1774 1.028
Curative intent (liver directed
treatment versus untreated liver
metastases)a
0.0184 0.360
Hepatic tumor number
(solitary versus multiple)
0.1563 1.767
Hepatic metastatic type
(synchronous versus
metachronous)
0.6218 1.190
Group A: combined curative resection of gastric cancers and hepatic
metastases. Group B: gastric and hepatic resection with curative intent,
where at least surgery was ultimately only palliative. Group B includes
radiofrequency ablation for hepatic metastases. Group C: palliative gastric
resection in the presence of untreated liver-only metastases.
aGroups A and B versus group C.
Figure 3. Overall survival of patients treated with radiofrequency ablation
(RFA) compared with curative resection (group A).
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prognostic factors
In the present study, although the total number of patients was
small, only the number of liver metastases (single versus
multiple) was a marginally significant prognostic factor for
survival after hepatic surgery with curative intent (P = 0.052)
(Table 6). The presence of metachronous hepatic metastases
was not a significant determinant for favorable prognosis after
hepatic resection in our study.
discussion
Previous studies describe the incidence of gastric cancers
metastasizing to the liver as 5%–14% [1–5]. In our series of
10 259 patients diagnosed with gastric adenocarcinomas, 1013
patients (9.9%) had liver metastases over the past decade.
Among them, 84 patients (8.3%) underwent gastric surgical
resections. As gastric cancer is still a major concern in Asian
nations, proper treatment strategy development for such
patients with metastases is necessary.
Among several approaches such as systemic chemotherapy,
radiation therapy, and surgical therapy, the effectiveness of
hepatic resection for metastases from gastric cancer has not
been well defined [2–4, 13–16]. In reality, very few patients with
gastric hepatic metastases are potential candidates for hepatic
resection because of multiple bilateral metastases or
extrahepatic diseases such as simultaneous peritoneal
dissemination or extensive lymph node metastases [2, 4, 27].
Hepatic resection, a potentially curative approach for patients
with liver metastases from colorectal carcinoma, carries a 5-year
survival rate of 30%–50%. In contrast, hepatic resection from
gastric carcinoma metastases has highly variable results and
a median survival time of 5–31 months, with 15%–77%
survival at 1 year and 0%–38% survival at 5 years [2, 3, 5, 9,
15–17, 26]. While the reasons for the differences in survival
rates are not clear, possible explanations include differences
in patient selection, screening programs, adjuvant
chemotherapy, and surgical techniques such as D2 versus D1
dissection. Thus, the clinical benefit of resection of hepatic
metastases from gastric carcinoma is not widely accepted and
remains controversial. However, as nonsurgical treatments
such as systemic or hepatic artery infusion chemotherapy also
do not achieve satisfactory results [2, 6, 7], the effort to evaluate
the potential role of hepatic resection is worthwhile.
In this retrospective study, we observed a survival benefit
of hepatic surgery (including RFA) with curative intent
(groups A and B) as compared with group C, as evidenced
by an improvement of 20.8% in the 5-year survival rate,
corresponding to a 64.0% reduction in the risk of death.
Even with incomplete resections in these patients, we found
that the survival rate was not significantly different from that
of the curatively resected patients. These results have the
limitation of patient selection bias because patients undergoing
surgical resection with curative intent would be expected to
have relatively good health and better prognosis. Even so,
there were no significant differences in characteristics of
primary gastric cancers, and the survival benefit was
consistently found even after adjusting for multiple
confounding factors that might affect survival. The median
survival duration of patients who received RFA for hepatic
metastases was 33.9 months, which was longer than previously
reported. Moreover, the median survival duration in patients
who had a positive surgical margin after hepatic surgery was
19.5 months.
Seventeen patients with liver-only metastases in group C
did not receive hepatic surgery even in the absence of distant
metastases or peritoneal seeding, usually due to the surgeon’s
decision that the hepatic metastases could not be resected
curatively. One patient had a single hepatic metastasis
metachronously at liver segment 6 after curative gastric
resection and adjuvant chemotherapy. He was treated with
second-line chemotherapy instead of hepatic resection. When
the survival of groups A and B versus C was analyzed after
adjusting for sex, age, number of liver metastases (solitary
versus multiple), and hepatic metastatic type (synchronous
versus metachronous), the hazard ratio for death was 0.360
in groups A and B compared with group C. These results
indicate the survival benefit of hepatic resection.
Compared with previous studies, our report is one of the
largest on surgical treatment of liver metastases in gastric
adenocarcinoma including both curatively and palliatively
resected patients. Five-year survival rates and median survival
time in our study were similar to those of other reports
showing the best results. Even though we included patients
with incomplete resections, we observed a longer median
survival compared with previous studies (Table 7). Roh et al.
[27] observed favorable results in patients who had a solitary
lesion in the liver. Sakamoto et al. and Okano et al. [3, 2]
also found favorable results when evaluating only curatively
resected patients. In contrast, Zacherl et al. [4] showed
disappointing results in their analysis of 15 patients who
underwent hepatic resection with curative intent. They found
that only 10 patients received a curative resection, showing
a significant survival benefit in curatively resected patients
compared with palliatively resected patients.
The clinicopathological characteristics related to the
prognosis of gastric cancer with hepatic metastases have not
Table 6. Variables affecting survival following hepatic resection with
curative intent (groups A and B) (n = 41)
Variable P value Hazard ratio
Hepatic tumor number
(solitary versus multiple)
0.0519 2.311
Age 0.4617 1.016
Sex 0.8126 0.879
Hepatic metastatic type
(synchronous versus
metachronous)
0.7241 0.830
Hepatic operation type
(including RFA)
0.8130 0.957
Group A: combined curative resection of gastric cancers and hepatic
metastases. Group B: gastric and hepatic resection with curative intent,
where at least surgery was ultimately only palliative. Group B includes
radiofrequency ablation for hepatic metastases. Group C: palliative gastric
resection in the presence of untreated liver-only metastases.
RFA, radiofrequency ablation.
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been comprehensively identified [4, 5, 9, 16, 25, 26, 28].
Whether surgical margin is a prognostic factor of survival in
patients with metastatic liver tumors remains controversial
[9, 13, 15], whereas resection margin is a significant prognostic
factor in colorectal metastatic cancer patients undergoing
hepatic resection [10, 29, 30]. In our study, positive surgical
margin did not greatly affect patient survival negatively in
agreement with the findings of Sakamoto [5]. This result
indicates that an extensive safety resection margin may not be
essential for better outcomes of hepatic resection in gastric
cancer. Positive surgical margins should be avoided if possible,
however, because long-term survival was not found in
margin-positive patients.
In the present study, although the total number of patients
was small, the number of liver metastases was a marginal
prognostic factor for survival after hepatic surgery with curative
intent (P = 0.0519). Okano et al. [2] reported 3-year survival
rates of 56% for a single metastasis and 0% for multiple
metastases, and the number of liver metastases is a significant
prognostic factor in other reports as well [3, 15]. In contrast,
the number of colorectal liver metastases is no longer
considered an important predictor of long-term survival [11].
The different results between colorectal and gastric metastases
are thought to reflect the aggressively infiltrative biologic
behavior of gastric cancer [2]. Our findings indicate that
surgical resection should be considered first for solitary liver
metastasis from gastric cancer.
Ambiru et al. [13] reported significantly longer survival in
patients with metachronous metastases (5-year survival, 29%)
than in those with synchronous disease (5-year survival, 6%).
Other authors have also reported favorable outcomes in
patients with metachronous metastases [2, 9]. We observed
no significant difference in survival between synchronous and
metachronous metastases in groups A and B (P = 0.7241).
Few reports have revealed patterns of recurrence after hepatic
resection for gastric metastases [5, 26]. Recurrence was
documented in 63.6% of the patients in the curatively
resected group. Relapse developed most commonly in the
liver (78.6%), indicating that the remaining liver should be
a focus for relapse monitoring. A sensible strategy for
improving survival would be close observation for a second
relapse in the liver and adjuvant chemotherapies after surgery.
We were unable to draw any conclusions about adjuvant
chemotherapy, and a multi-institutional prospective
randomized trial will be needed for this issue. Sex, age,
number of liver metastases (solitary versus multiple), hepatic
metastatic type (synchronous versus metachronous), and
surgical type of hepatic resection did not affect relapse-free
survival.
In conclusion, our results show that surgery for liver
metastases arising from gastric adenocarcinoma is reasonable
if complete resection seems feasible after careful preoperative
staging, even if complete resection is not actually achieved.
Hepatic resection should be therefore being considered as an
option for patients who had gastric cancer with hepatic
metastases.
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